New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. Drug patent…
The post New tentative approval for Watson Labs drug dienoge…


Which pharmaceutical companies have the most drug patents in China?

This chart shows the pharmaceutical companies with the most patents in China. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…
The post Which pharmaceutical companies have the most drug patent…


New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. Drug patent…
The post New tentative approval for Watson Labs drug dienoge…


Which pharmaceutical companies have the most drug patents in South Africa?

This chart shows the pharmaceutical companies with the most patents in South Africa. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…
The post Which pharmaceutical companies have the most drug pa…


Drug Patent Expirations for the Week of December 2, 2018

VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,107,986 Expiration: Dec 6, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]
The post…


New patent for Cubist Pharms drug ZERBAXA

Annual Drug Patent Expirations for ZERBAXA Zerbaxa is a drug marketed by Cubist Pharms Llc and is included in one NDA. It is available from one supplier. There are seven…
The post New patent for Cubist Pharms drug ZERBAXA appeared first on DrugPatentWa…


New patent for Sanofi-aventis Us drug SOLIQUA 100/33

Annual Drug Patent Expirations for SOLIQUA+100%2F33 Soliqua 100/33 is a drug marketed by Sanofi-aventis Us and is included in one NDA. It is available from one supplier. There are twenty-five…
The post New patent for Sanofi-aventis Us drug SOLIQUA 100/…


Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases

This paper was originally published by Emanuel Almeida Moreira de Oliveira and Karen Luise Lang in Journal of Applied Pharmaceutical Science Vol. 8(08), pp 157-165, August, 2018 under the terms of the…
The post Drug Repositioning: Concept, Classificati…


PBMs, Formularies, and Rebates: What Investors Should Know

There is no simple way to explain drug prices, particularly in the US market, where drug prices vary considerably more than they do in other countries. Most Americans are familiar…
The post PBMs, Formularies, and Rebates: What Investors Should Know app…


The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

This article was originally published by Gerard T. Vondeling, Qi Cao, Maarten J. Postma, and Mark H. Rozenbaum in Applied Health Economics and Health Policy (2018) pp.1-8 under a Creative Commons Attribution-NonCommercial…
The post The Impact of Patent…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: